Observational look at treatment patterns and outcomes in HR-positive, HER2-negative metastatic breast cancer in China
Official title: VERITAS Longitudinal Real-world Registry of HR+/HER2- mBC to Understand Treatment Pattern and Clinical Outcomes in HR+/HER2- mBC
Run by AstraZeneca · NCT07743944 · Data updated 2026-11-12
This real-world study tests how patients with HR+/HER2- metastatic breast cancer in China are treated and how they fare over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | August 5, 2026 |
| Main results expected | August 4, 2031 |
| Study ends | August 4, 2031 |
| Registry record updated | August 4, 2026 |
| Trial ID | NCT07743944 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) in China with unresectable or metastatic HR+/HER2- breast cancer planning to start or recently started second-line therapy, able to consent or exempted for consent under applicable rules.
✕Probably not a fit
Patients enrolled who do not receive systemic therapy in the second-line window or whose treatment paths diverge from typical practice may see limited applicability of findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study combines retrospective and prospective data to describe patient demographics, clinical characteristics, genetic test results, treatment patterns, and outcomes in HR+/HER2- unresectable or metastatic breast cancer (including HER2-low/ultralow/null) in China. It also explores outcomes by treatment regimens, collects patient-reported outcomes and quality of life, and analyzes healthcare resource use and costs overall and by line of therapy. The study does not involve a randomized intervention and will observe patients from the index date forward and backward as applicable. Enrollment is centered at The First Affiliated Hospital of Nanjing Medical University, with AstraZeneca as lead sponsor and no collaborating sites listed.
Why it matters
Potential benefit: If successful, it could provide real-world evidence on treatment patterns and outcomes to inform care decisions for Chinese patients with metastatic HR+/HER2- breast cancer.
How similar studies have gone: Previous real-world observational efforts in breast cancer have provided actionable insights, though this specific population and regional setting are relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria \* Must be competent and able to comprehend, sign, and date an Institutional Review Board or Institutional Ethics Committee approved Informed consent form (ICF) before participating in the study. OR Eligible for exemption from informed consent (for patients who die or became lost to follow-up within 2 months of initiating 2L therapy). \* Chinese men or women ≥ 18 years old at time of consent. \* Pathologically documented breast cancer that: a) is unresectable or metastatic. b) is HR+/HER2- (IHC 2+/ISH- or IHC 1+ or IHC 0, with/without membrane staining) based on the most recent test result \* Planning to initiate 2L treatment or initiated 2L systemic therapy within 2 months prior enrollment as per the prescription or medical records. Exclusion Criteria \* Patients who plan to participate in any blinded interventional clinical trial in 2L setting.
Where it's running
-
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)
Nanjing, Jiangsu, China Recruiting
Study contacts
- Study coordinator: Astra Zeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.